

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 23, 2016

**BIO-PATH HOLDINGS, INC.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-36333</b> (Commission File Number)	<b>87-0652870</b> (IRS Employer Identification No.)
<b>4710 Bellaire Boulevard, Suite 210, Bellaire, Texas</b> (Address of principal executive offices)		<b>77401</b> (Zip Code)

(832) 742-1357  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

On March 23, 2016, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center.” A copy of such press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
---------------------------	--------------------

99.1	Press Release dated March 23, 2016
------	------------------------------------

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **BIO-PATH HOLDINGS, INC.**

Dated: March 24, 2016

By: /s/ Peter H. Nielsen  
Peter H. Nielsen  
President and Chief Executive Officer

---

## **EXHIBIT INDEX**

Exhibit  
Number

Description

99.1

Press Release dated March 23, 2016

---



**Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with  
The University of Texas Southwestern Medical Center**

**HOUSTON—March 23, 2016** — Bio-Path Holdings, Inc., (NASDAQ: BPTH) (“Bio-Path”), a biotechnology company leveraging its proprietary DNAAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid drugs, today announced that it has entered a sponsored research agreement with The University of Texas Southwestern Medical Center (UT Southwestern) to evaluate Bio-Path’s clinical pipeline for its efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. SLE is a chronic autoimmune disorder that presents an array of symptoms, including skin lesions, heart inflammation, joint pain, kidney failure and neuropsychiatric disorders. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path’s lead product candidate, which is currently in a Phase II study for blood cancers.

The study’s principal investigators will be Laurie Davis, Ph.D., associate professor in the department of internal medicine at UT Southwestern, and Anne Satterthwaite, Ph.D., Peggy Chavellier Professor of Arthritis Research and Treatment, and Southwestern Medical Foundation Scholar in Biomedical Research. Dr. Davis’ research has included investigations into new markers of human autoimmunity and disease severity of autoimmune disorders, including SLE. Her current research seeks to elucidate molecular pathways that are altered by autoimmune diseases and could identify novel therapeutic targets. Dr. Satterthwaite’s research at UT Southwestern has focused primarily on the contribution of B-cell signaling pathways to B-cell tolerance and autoimmunity.

“We are privileged to join forces with Drs. Davis and Satterthwaite,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “Their combined expertise and research in autoimmune disorders make them well suited to lead this study. Together, we look forward to assessing the ability of Bio-Path’s product candidates to down-regulate the immune response and potentially meet the needs of patients suffering from SLE and other autoimmune disorders.”

**About Bio-Path Holdings, Inc.**

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company’s website at <http://www.biopathholdings.com>.

**Forward-Looking Statements**

*Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

# # #

---

**Contact Information:**

**Investors**

Doug Morris  
Investor Relations  
Bio-Path Holdings, Inc.  
832-742-1369

Steve Silver  
Rx Communications Group, LLC  
917-322-2569  
[ssilver@rxir.com](mailto:ssilver@rxir.com)

**Media**

Tony Plohoros  
6 Degrees  
908-591-2839  
[tplohoros@6degreespr.com](mailto:tplohoros@6degreespr.com)

---